Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Mol Neurobiol. 2014 Apr 15;51(1):43–56. doi: 10.1007/s12035-014-8691-z

Fig 7. Therapeutic rAAV9-IgVL5D3 injection decreases Aβ-immunoreactive deposits in the right hippocampus and fibrillar Aβ-deposits in the right neocortex.

Fig 7

Five months after rAAV9-IgVL5D3 or PBS injection, TgAPPswe/PS1dE9 mice were terminated and Aβ deposits in the brain were visualized and quantified by morphometric analysis. Aβ deposits are visualized by 6E10 antibody (a, b) and thioflavin S (c, d). The percentages of immunoreactive or fluorescent areas for 6E10 (b) and thioflavin S (d), respectively, are shown as bar graphs. The values shown are the mean ± SEM. PBS: PBS-injected mouse, 5D3: rAAV9-IgVL5D3-injected mouse. Scale bars, 1 mm.